SCHEMBL21163271

SCHEMBL21163271

Nc1nc2c(ncn2[C@@H]2O[C@H](COP(=O)(O)O[C@H]3[C@@H](O)[C@H](n4cnc5c(=O)[nH]c(N)nc54)O[C@@H]3COP(=O)(O)OP(=O)(O)OP(=O)(O)OC[C@H]3O[C@@H](n4cnc5c(=O)[nH]c(N)nc54)[C@H](O)[C@@H]3O)[C@@H](O)[C@H]2O)c(=O)[nH]1

nearest known ligand 0.77

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
TGM2 P21980 1/20 0.77
FUT5 Q11128 1/20 0.73
KRAS P01116 2/20 0.72
NT5E P21589 1/20 0.72
P2RX3 P56373 3/20 0.67
P2RY2 P41231 3/20 0.65
P2RY6 Q15077 2/20 0.65
P2RY4 P51582 1/20 0.65
RNASEL Q05823 3/20 0.65
P2RY1 P47900 5/20 0.63
P2RX1 P51575 2/20 0.63
P2RX4 Q99571 2/20 0.63
SRC P12931 1/20 0.63
P2RX2 Q9UBL9 1/20 0.63
ALDH1A1 P00352 1/20 0.63
SMN1; SMN2 Q16637 1/20 0.63
DCPS Q96C86 1/20 0.62
P2RY11 Q96G91 2/20 0.62
ENPP1 P22413 1/20 0.62

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21163269 1.00 TGM2 (0.77) TGM2FUT5KRASNT5EP2RX3
SCHEMBL18320601 0.95 NT5E (0.72) TGM2FUT5KRASNT5EP2RY2
SCHEMBL22678637 0.95 TGM2 (0.69) TGM2FUT5KRASNT5EP2RX3
SCHEMBL29486374 0.94 NT5E (0.71) TGM2FUT5KRASNT5EP2RX3
SCHEMBL29486372 0.94 NT5E (0.71) TGM2FUT5KRASNT5EP2RX3
SCHEMBL29822597 0.94 NT5E (0.71) TGM2FUT5KRASNT5EP2RX3
SCHEMBL29353975 0.94 NT5E (0.71) TGM2FUT5KRASNT5EP2RX3
SCHEMBL21067722 0.94 TGM2 (0.85) TGM2FUT5KRASNT5EP2RX3
SCHEMBL18769114 0.94 TGM2 (0.85) TGM2FUT5KRASNT5EP2RX3
SCHEMBL851357 0.94 TGM2 (0.85) TGM2FUT5KRASNT5EP2RX3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20190211368-A1 TRINUCLEOTIDE MRNA CAP ANALOGS MODERNATX, INC. 2019-07-11 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190211368-A1 TRINUCLEOTIDE MRNA CAP ANALOGS RNGTT, RNMT, CPSF7 TGM2 3089/4885FUT5 2623/4885KRAS 2731/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.